Evidence map›Paper›PMID 41987891›Full record

ArticleFrontiers in endocrinology2026

Exogenous glucocorticoid dose impacts circulating microRNA expression in patients with adrenal insufficiency due to 21-hydroxylase deficiency.

Vipula Kolli, Jacob Trick, Annie Schulman, James R Iben, Cameron Padilla, Tianwei Li, Fabio Rueda Faucz, Deborah P Merke

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vipula KolliDepartment of Pediatrics, National Institutes of Health Clinical Center, Bethesda, MD, United States.
Jacob TrickDepartment of Pediatrics, National Institutes of Health Clinical Center, Bethesda, MD, United States.
Annie SchulmanDepartment of Pediatrics, National Institutes of Health Clinical Center, Bethesda, MD, United States.
James R IbenThe Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, United States.
Cameron PadillaThe Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, United States.
Tianwei LiThe Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, United States.
Fabio Rueda FauczThe Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, United States.
Deborah P MerkeDepartment of Pediatrics, National Institutes of Health Clinical Center, Bethesda, MD, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Patients with adrenal insufficiency due to 21-hydroxylase deficiency (21-OHD) are often exposed to supraphysiologic doses of glucocorticoids (GCs), which can augment metabolic dysfunction by altering glucose, lipid and protein metabolism. Exogenous GCs also fail to mimic the natural circadian rhythm of cortisol secretion. MicroRNAs (miRNAs) are important regulators of gene expression involved in various biological and pathological processes. GCs can regulate miRNAs and in turn miRNAs can modulate GC receptor (GR) activity influencing GR-mediated activity. In this pilot study, we examine the effects of exogenous GCs on circulating miRNA levels in patients with adrenal insufficiency due to classic 21-OHD. Patients/methods: Blood samples were collected from 37 patients with classic 21-OHD. Comprehensive miRNA-seq transcriptomic profiling was performed followed by functional enrichment analysis. Patients on different GC types (short- Results: Seven miRNAs (hsa-miR-320a, hsa-miR-122, hsa-let-7b, hsa-let-7i, hsa-miR-4747, hsa-miR3591, hsa-miR-4732) were differentially expressed in patients receiving high-dose GC therapy compared to those receiving physiologic doses ( Conclusions: In patients with CAH, daily GC dose > 18 mg/m

Indexed as

Adrenal Hyperplasia, CongenitalAdrenal InsufficiencyCirculating MicroRNAGlucocorticoidsMicroRNAsAdolescentAdultChildFemaleGene Expression ProfilingGene Expression RegulationHumansMalePilot ProjectsYoung AdultCirculating MicroRNAGlucocorticoidsMicroRNAs21-hydroxylase deficiencyadrenal insufficiencycongenital adrenal hyperplasiaenrichment analysisglucocorticoidmicroRNA

Identifiers

PMID41987891
PMCPMC13076110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.